Drug Type Small molecule drug |
Synonyms LP 108, LP-108 |
Target |
Action inhibitors |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC48H55ClN8O7S |
InChIKeyCCDRQWAEZGRMTP-WJOKGBTCSA-N |
CAS Registry2291166-56-6 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Lymphocytic Leukemia | Phase 2 | China | - | |
| Small Lymphocytic Lymphoma | Phase 2 | China | - | |
| Acute Myeloid Leukemia | Phase 1 | United States | 06 Jul 2020 | |
| Acute Myeloid Leukemia | Phase 1 | China | 06 Jul 2020 | |
| Acute Myeloid Leukemia | Phase 1 | Spain | 06 Jul 2020 | |
| Acute Myeloid Leukemia | Phase 1 | United Kingdom | 06 Jul 2020 | |
| Adult Acute Myeloblastic Leukemia | Phase 1 | United States | 06 Jul 2020 | |
| Adult Acute Myeloblastic Leukemia | Phase 1 | Spain | 06 Jul 2020 | |
| Anemia, Refractory, With Excess of Blasts | Phase 1 | United States | 06 Jul 2020 | |
| Anemia, Refractory, With Excess of Blasts | Phase 1 | Spain | 06 Jul 2020 |
NCT04356846 (EHA2024) Manual | Phase 1 | 33 | LP-108 at dose levels from 20 mg/day to 800 mg/day | lyjrtdsowq(jjynwcrsul) = ynwhrjokeg tukkcfynxm (glqzmnqwzt ) View more | Positive | 14 May 2024 | |
Phase 1 | 32 | szubylrvgj(gommqlxgno) = kasdbiargt itnvzeukct (gfdhsakijb ) View more | - | 08 Jun 2023 | |||
szubylrvgj(gommqlxgno) = dqfyhhnmvr itnvzeukct (gfdhsakijb ) View more | |||||||
Phase 1 | 49 | vhvlpjbrwm(lneuyxocgg) = naizwxldfh mnihscfxau (illjnvfeyp ) View more | - | 08 Jun 2023 | |||
NCT04356846 (EHA2022) Manual | Phase 1 | 19 | uemiqmvruq(stxszcpivu) = gqlqkzanuw asmoaldenr (hukxcfknqh ) View more | Positive | 12 May 2022 |





